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Background: Outcome of consecutive patients with locally advanced non-small cell lung cancer and histopathologically
proven mediastional lymph node metastases treated with induction chemotherapy, neoadjuvant radiochemotherapy
and thoracotomy at the West German Cancer Center between 08/2000 and 06/2012 was analysed. A clinico-
pathological prognostic model for survival was built including partial or complete response according to computed
tomography imaging (CT) as clinical parameters as well as pathologic complete remission (pCR) and mediastinal nodal
clearance (MNC) as histopathologic factors.
Methods: Proportional hazard analysis (PHA) and recursive partitioning analysis (RPA) were used to identify prognostic
factors for survival. Long-term survival was defined as survival≥ 36 months.
Results: A total of 157 patients were treated, median follow-up was 97 months. Among these patients, pCR and MNC
were observed in 41 and 85 patients, respectively. Overall survival was 56 ± 4% and 36 ± 4% at 24 and 60 months,
respectively. Sensitivities of pCR and MNC to detect long-term survivors were 38% and 61%, specificities were
84% and 52%, respectively.
Multivariable survival analysis revealed pCR, cN3 category, and gender, as prognostic factors at a level of α < 0.05.
Considering only preoperative available parameters, CT response became significant. Classifying patients with a
predicted hazard above the median as high risk group and the remaining as low risk patients yielded better
separation of the survival curves by the inclusion of histopathologic factors than by preoperative factors alone
(p < 0.0001, log rank test). Using RPA, pCR was identified as the top prognostic factor above clinical factors
(p = 0.0006). No long term survivors were observed in patients with cT3-4 cN3 tumors without pCR.
Conclusions: pCR is the dominant histopathologic response parameter and improves prognostic classifiers,
based on clinical parameters. The validated prognostic model can be used to estimate individual prognosis and
forms a basis for patient selection for treatment intensification.
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Mediastinal nodal clearance (MNC) defined as sterilization
of initially involved (cN2, cN3) mediastinal lymph nodes
after neoadjuvant radiochemotherapy followed by surgery
(ypN0) was identified as a prognostic marker for long-term
survival for stage III non-small-cell lung cancer (NSCLC)
[1-5]. In these trials, the proportion of patients with MNC
among patients who received thoracotomies after neoadju-
vant radiochemotherapy was approximately 50%. MNC
was taken as a surrogate endpoint for the treatment effect
of neoadjuvant radiochemotherapy and represented the
primary endpoint of the Radiation Therapy Oncology
Group phase II trial 02–29 [6]. In this trial, full dose radio-
therapy to 61.2 Gy in conventional fractionation and
weekly concurrent carboplatin/paclitaxel chemotherapy
was given. Nodal clearance was achieved in 63% of patients
with pathologically proven N2 or N3 involvement receiving
thoracotomy, but only 8% had a pathologic complete re-
mission (pCR), defined as sterilization of tumor tissue at all
involved sites (primary and lymph nodes). Generally, pCR
is found at lower frequencies than MNC in patients under-
going thoracotomy after neoadjuvant radiochemotherapy
and has been observed in 8-39% of patients in larger series
[1,2,5-10]. Others found that pCR is an important prognos-
tic factor for survival after neoadjuvant radiochemotherapy
and resection [9-11].
In this large retrospective monoinstitutional study, we
evaluated the prognostic strengths of patient characteris-
tics, treatment variables and histopathologic response
parameters within a prognostic model for survival in a
comprehensive group of patients with locally advanced
NSCLC and histopathologically proven mediastinal
lymph node metastases undergoing neoadjuvant radio-
chemotherapy and thoracotomy. In particular, the prog-
nostic values of pCR and MNC on long-term survival
were analyzed.
Methods
This observational study included data from consecutive
patients with stage IIIA/IIIB NSCLC according to the
UICC classification, 7th edition 2009, who were treated
at the West German Cancer Center between August
2000 and June 2012.
The study has been approved by the Ethics committee
of the University of Duisburg-Essen, Essen, Germany.
All treatments were performed in accordance with the
German Legislation of Radiation Protection. Written in-
formed consent was obtained from all patients prior to
treatment initiation.
Following induction chemotherapy and neoadjuvant
chemoradiotherapy, all patients were resected at the
Division of Thoracic Surgery, Ruhrlandklinik, Essen. All
patients were staged by mediastinoscopy or endobronchial
ultrasound-guided needle aspiration to confirm cN2 orcN3 status by histo- or cytopathology. The additional
workup included computed tomography (CT) scans of the
thorax and abdomen and bone scans, or whole body
PET/CT which became available at our institution in
2002. In addition, CT or MRI scans of the brain were
performed in all patients. All patients were discussed in
the multidisciplinary tumor board of the lung cancer
center of the West German Cancer Center. Following
three cycles of induction chemotherapy (cisplatin/pacli-
taxel doublets predominantly given throughout the whole
time period, cisplatin/etoposide was administered to pa-
tients prior to 2007) concurrent radiochemotherapy was
initiated [7]. Cisplatinum-based doublets were used during
the concurrent chemoradiotherapy phase. Before 2004,
etoposide was predominantly applied which was later re-
placed by vinorelbine as combination partner for cisplatin.
Patients received conventionally fractionated radiotherapy
to 44–46 Gy at 2 Gy per fraction, or accelerated hyperfrac-
tionated radiotherapy at 2 × 1. 5 Gy per day, ≥6 h interval,
5 days a week, up to a total dose of 45 Gy. Three-
dimensional treatment planning was performed for all pa-
tients based on planning CT scans following induction
chemotherapy. The planning procedure has been previ-
ously described in detail [7].
During the last week of neoadjuvant radiochemother-
apy, patients underwent restaging CT-scans and were
again discussed in the multidisciplinary tumor board.
Preoperatively, re-mediastinoscopy was performed in all
patients with initial N3-disease to define the response to
induction treatment. Patients with positive contralateral
nodes at repeated mediastinoscopy were excluded from
surgery and were offered definitive concurrent radioche-
motherapy. Those patients who were evaluated as resect-
able by the thoracic surgeon at that time point were
offered surgery. Criteria of resectability have been de-
scribed earlier [12]. Patients underwent a preoperative
cardiovascular risk assessment including a cardiopulmo-
nary function test. Patients were ineligible due to a pre-
dicted postoperative forced expiratory volume at 1 s of
less than 1 liter (quantitative ventilation–perfusion lung
scanning), cardiac infarction or unstable angina pectoris
during the 6 months before study entry or cardiac failure
of class III or greater (NYHA criteria). If re-evaluation
showed continuing medical/functional and technical op-
erability, patients were taken to thoracotomy 3–5 weeks
after the end of radiation treatment.
After treatment completion, no adjuvant treatment
was planned and patients were monitored every three
months during the first year of follow-up. Thereafter,
examination intervals were set to 4–6 months. Time to
progression (TTP) and overall survival (OS) were calcu-
lated from the start of the induction chemotherapy. For
non-progressing patients, TTP was calculated as cen-
sored at the time of the last follow-up visit. Survival
Pöttgen et al. BMC Cancer  (2015) 15:363 Page 3 of 10information was updated from the local residents regis-
tration offices between 1st and 15th of September 2013.
Toxicities were assessed using CTC (v. 2) scores [13].
Pathologic complete response (pCR) was defined as
complete disappearance of vital tumor cells at all initially
involved tumor sites (ypT0 ypN0) assessed by histopath-
ologic examination of the resection specimen. Regres-
sion grades 2A and 2B were defined as evidence of
therapy-induced tumor regression with >10% and <10%
of vital tumor cells remaining, respectively [14]. MNC
was defined as ypN0. Histopathologic complete regres-
sion at the primary tumor site only (pCR-T) was defined
as ypT0.
Long-term survivors were defined as patients living
≥36 months since start of induction chemotherapy.
Twenty percent of all deceased patients (n = 98) of this
cohort fulfilled the criteria for long-term survivors. On
the other hand, 47% of the living patients had a follow-
up time of less than 36 months. For these patients, the
conditional probability p was calculated to survive 3 years
having the observed survival time according to a back-
ward selection proportional hazard model. These pa-
tients were included in the analysis with weight p as
long-term survivors and with weight 1-p as short-term
survivors, respectively.
Sensitivities and specificities of the histopathologic re-
gression parameters to predict long-term survival as well
as the positive likelihood ratio = sensitivity/(1-specificity)
together with its 95% confidence limits and the Cochrane-
Mantel-Haenszel (CMH) test for the association of the
histopathologic response parameters with survival were
calculated with the procedure FREQ using SAS statistical
software version 9.2 (Cary, NC). Proportional hazard re-
gression analysis (PHA) was performed with the proced-
ure PHREG. The following clinical explanatory variables
were included in the full proportional hazard regression
model. Patient-dependent variables: age as a continuous
variable, gender, Charlson comorbidity score. Tumor char-
acteristics: cN2 (yes vs. no), cN3, Pancoast tumor localisa-
tion, cT3, cT4, stage IIB, adenocarcinoma (yes vs. no),
squamous cell carcinoma (yes vs. no), grade 3 carcinoma,
number of histopathologically proven mediastinal lymph
node metastases at initial staging. Treatment characteris-
tics: hyperfractionated accelerated radiotherapy (yes vs.
no), cisplatin/paclitaxel doublet as induction chemother-
apy, cisplatin/vinorelbine as concurrent chemotherapy,
pneumonectomy, R1 resection, R2 resection. In addition,
the following histopathologic and clinical response vari-
ables were included: pCR, MNC, regression grade (regres-
sion grade ≥ 2B, regression grade > 2A, ypT0), response to
neoadjuvant radiochemotherapy according to computed
tomography imaging studies before and after neoadjuvant
radiochemotherapy according to the RECIST criteria (PD/
NC versus PR/CR) [15]. A backward variable eliminationprocedure was used to retain variables in the model sig-
nificant at α = 0.05. The proportional hazard assump-
tion was studied by Schoenfeld partial residuals and
their correlation with the rank order of failure times
and by introducing time dependent interaction terms
for the covariates in the model to detect a possible
trend over time of the hazard ratio [16,17].
Prognostic models were derived using the PHA variable
estimates after backward elimination with or without in-
clusion of the histopathologic parameters. The sample was
split in equally sized high risk or low risk groups depend-
ing on whether the prognostic index, defined as the vector
product of the PHA regression coefficients and the pa-
tients’ expression of prognostic parameters constituting a
factor of the hazard function, was located above or below
the median, respectively. Ten-fold cross-validation was
used to evaluate the predictive accuracy of the prognostic
model on a data set independent of the one used for
model building. Therefore, the whole sample of 157 pa-
tients was split into 10 approximately equally sized sub-
groups by random numbers. For each k-th subgroup, the
prognostic model was developed from scratch on the basis
of the data from the 9 other subgroups by fitting the PHA
model with backward elimination. This model was then
used to split the k-th subgroup into a high risk and low
risk group. Not necessarily the same variables had to stay
in the model for each of the k loops of cross-validation.
Repeating this process for all subgroups resulted in a split
of the whole sample into a high and a low risk group. The
respective Kaplan-Meier curves were termed as cross-
validated Kaplan Meier curves [18]. The prognostic model
containing clinical and histopathological covariables was
evaluated against the standard model using the difference
of the log-rank statistics for comparison of the cross-
validated Kaplan Meier curves of the high and low risk
groups according to both models as a test statistic [18].
For regression tree growing during recursive partition-
ing analysis (RPA), the log rank test was used as the split-
ting criterion [19]. The dichotomic prognostic parameter
that results in the largest separation of 5 year survival
at each node with a p-value < 0.05 was selected as the
criterion for this node.
Results
Median follow-up for survival of the entire cohort was
97 months. Patient characteristics have been reported
in a previous publication on the effects of accelerated
hyperfractionation on pCR and are summarized in
Table 1 [7]. One hundred fifty-seven patients have been
resected out of 164 who underwent the induction che-
moradiotherapy phase completely. Eight patients were
not resected either due to comorbidities (n = 3), persistent
contralateral lymph node involvement at remediastino-
scopy (n = 3), or patients’ refusal (n = 2), and received






median (range) 59 · 0 (34–74)
Primary tumor and lymph node classification
cT1-3 N2 81 52
cT1-3 N3 35 22
cT4 N2 37 24
cT4 N3 4 2
Histology
Squamous Cell Carcinoma 58 37
Adenocarcinoma 75 48
Large Cell Carcinoma 16 10








Sulcus Superior (Pancoast) 9 6
Upper Lobe 95 60
Middle Lobe/Centrally located 30 19















Thoracotomy without resection 1 1
Table 1 Patient characteristics (Continued)
Resection
microscopic complete (R0) 143 92
microscopic incomplete (R1) 9 6
macroscopic incomplete (R2) 4 2
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ment (n = 3), respectively. Pneumonectomies were per-
formed in 40 patients. In this cohort, none of the patients
died within 30 days after surgery. Figure 1 shows the sur-
vival curve of all patients who underwent tumor resection
(n = 157). Two-, three-, and five- year survival was 56 ±
4%, 46 ± 4%, and 36 ± 4%, respectively.Sensitivity and specificity of histopathologic regression
parameters to predict long-term survival
Sensitivity and specificity as well as the likelihood ratio
were analyzed for the different histopathologic regression
parameters to predict long-term survival. For the entire
group of patients, pCR had the highest likelihood ratio
among all histopathologic parameters that were signifi-
cantly different from the value 1 for a useless test (Table 2).
pCR and pCR-T (pathologic complete remission in the
primary tumor in contrast to complete remission of tumor
and mediastinal nodes) carry similar information and the
vast majority (n = 41) of the 46 patients with pCR-T also
achieved pCR. Decreasing the cut-off level for histopatho-
logic tumor regression required for a positive histopatho-
logic response from pCR over regression grades 2B to 2A
(Reg-grade ≥2B to Reg-grade ≥2A) decreased the likeli-
hood ratio for the association of the surrogate marker with
long-term survival. Sensitivity of pCR as a predictor of
survival was low (0.38), indicating that the majority of
long-term survivors not achieving pCR following pre-
operative therapy were salvaged by tumor resection. MNC
was found in approximately twice as many patients as
pCR-T or pCR. This suggests a higher radiosensitivity of
lymph node metastases as compared to the primary tu-
mors. Sensitivity of MNC to predict survival was higher
than that of pCR-T or pCR, but specificity was poor. The
positive likelihood ratio for MNC was not significantly
different from 1 (Table 2).Proportional hazard analysis of the clinical and
pathological variables on survival
Proportional hazard regression containing all clinical and
pathological variables found pCR, cN3, and gender as
independent prognostic factors for survival using back-
ward elimination of non-significant variables for re-
duced model selection at a significance level of α = 0.05
(model (1), Table 3).
Figure 1 Survival curve for all patients of this study.
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ated with survival, indicating the absence of unrecognized
period-dependent confounders.
With respect to the other histopathologic parameters,
neither MNC without pCR nor Reg-grade ≥2B, or Reg-
grade ≥2A without pCR carried important prognostic in-
formation in addition to pCR. After adjustment of the
other prognostic factors, patients with MNC without
pCR had a similar prognosis as patients without MNC
and without pCR. 15 of 44 patients with MNC but with-
out pCR were long-term survivors, 16 had known pro-
gression of disease (11 at distant and 2 at locoregional
sites only, and 3 at both sites).
Response according to CT studies was not selected as
an independent prognostic factor in addition to pCR.
No significant deviation from the proportional hazard
assumption was found by analysis of the correlation be-
tween the Schoenfeld residuals and the rank order of fail-
ure times. Furthermore, time dependence of the hazard
ratio did not become significant (p > 0.05).Table 2 Sensitivity and specificity for the respective histopath
Patients with cN2-3 status
Number of patients Long-term survivors Sensi
all patients 157 72
pCR 41 28 0.38 (0
Reg-grade≥ 2B 72 40 0.56 (0
Reg-grade≥ 2A 135 66 0.92 (0
pCR-T 46 29 0.40 (0
MNC 85 44 0.61 (0
CMH measures the strength of association between the histopathologic response v
patient survival ≥ 36 months.In addition, the PHA parameter estimates from a
standard model (model (2)) containing only pretreat-
ment patient and tumor dependent clinical parameters
with backward selection are shown in Table 3. Response
according to CT studies became significant in the ab-
sence of histopathologic response parameters.
Both models were used to classify patients into equally
sized high and low risk groups. A patient was assigned
to the high risk group if the estimated hazard according
to the model was larger than the median value in the
sample of patients. To create continuous predictors, age
was added as a continuous variable to the models. Older
age was non-significantly associated with poorer survival
by a hazard ratio of 1.02 per year increase. The model
including histopathologic parameters led to a better sep-
aration of the survival curves between the high risk and
low risk groups. The log-rank chi-square test statistic for
the separation of the survival curves of the high and low
risks groups was significantly larger using the model in-
cluding pCR than the model including preoperativeologic response criterium to predict long term survival
tivity Specificity Sensitivity/(1-specificity) CMH-test
.27–0.50) 0.84 (0.77–0.92) 2.46 (1.39–4.38) p = 0.0012
.44–0.67) 0.62 (0.52–0.73) 1.48 (1.05–2.08) p = 0.025
.85–0.98) 0.19 (0.11–0.27) 1.13 (0.99–1.28) p = 0.057
.29–0.51) 0.80 (0.71–0.88) 1.96 (1.18–3.25) p = 0.008
.50–0.72) 0.52 (0.41–0.62) 1.26 (0.95–1.69) p = 0.11
ariable and long term survival which was defined as
Table 3 Significant prognostic variables from proportional hazard regression analysis of survival data
model (1) containing clinical + pathol. covariates standard model (2) containing clinical covariates alone
variable Hazard ratio p-value Hazard ratio p-value
pCR 0.41 (0.25–0.67) p = 0.0003 not included
cN3 1.52 (1.01–2.29) p = 0.047 1.59 (1.06–2.39) p = 0.027
gender (female) 0.57 (0.38–0.87) p = 0.008 0.63 (0.42–0.94) p = 0.025
CT - tumor response Backward eliminated n.s. 0.59 (0.39–0.91) p = 0.017
Model (1) contains all clinical and pathological covariates, as described under Methods. Backward elimination of non-significant variables was used for reduced
model selection. CT-tumor response: partial or complete response after neoadjuvant radiochemotherapy in comparison to the pretreatment computed tomography
imaging study.
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cross-validation was performed in order to estimate the
predictive value of both models on a data set independent
of that one used for the model building process. The
cross-validated Kaplan Meier curves for the high and low
risk groups according to the model including histopatho-
logic variables are shown in Figure 2. All 41 with pCR
were sorted in the cross validated low risk group. A com-
parison of the log-rank statistics for the differences be-
tween the cross-validated Kaplan Meier curves for the
high and low risk groups revealed a better separation by
the model including histopathologic parameters than by
the model including preoperative available parameters
alone (p = 0.017, chi2 test).
In addition, we analyzed whether tumor response ac-
cording to the CT-studies after neoadjuvant radioche-
motherapy might predict pCR. The Spearman rank
correlation between the response according to the CT-
studies (PD/NC vs. PR/CR) and pCR was 0.21 (p < 0.05).
None of the patients in this study, all of whom underwentFigure 2 Cross-validated survival curves for patients classified as high and
well as age. The survival difference was significant using the log rank test (surgery, had progressive disease after neoadjuvant radio-
chemotherapy. Among the 123 responding patients, there
were 38 with pCR, while among the 34 non-responding
patients only 3 were detected with pCR. The prognostic
model (2) based on patient and tumor dependent pre-
treatment factors alone could also be improved by intro-
duction of CT-response as an independent prognostic
factor when histopathologic response parameters were not
considered for prediction. The backward elimination
procedure retained CT-response as a prognostic factor
(hazard ratio 0.59 (0.39–0.91) for responding patients,
p = 0.017, chi2 test).
PET/CT investigations before and after induction
treatment were only available in less than half of the
patients (n = 58). In an exploratory subgroup-analysis,
deltaSUVmax in the primary tumor (= (SUVmax after
induction chemotherapy)/(SUVmax before induction
chemotherapy)) showed a positive correlation with pCR
when using a cutoff-level of 0.3 separating responders
(deltaSUVmax < 0.3) from non-responders (deltaSUVmax≥ 0.3;low risk including significant clinical and histopathologic parameters as
p = 0.006).
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patients showed pCR in 17 responders, only 8 of 41
non-responders were found with pCR. When using CT-
response criteria in this subgroup, 16 pCR patients out
of 48 responders versus one pCR patient out of 10 non-
responders were identified (Spearman rank correlation
0.19, p = 0.097). Due to the small number of patients,
deltaSUVmax was not included in the prognostic model
for survival.
Recursive partitioning analysis (RPA) including all
clinical and pathological predictor variables led to the
regression tree shown in Figure 3. The top node contains
pCR as the predictor variable. For patients without pCR,
the cN3 lymph node category became important. For cN3
patients, high T category was selected as additional split to
obtain prognostic subgroups.
Fourteen long term survivors were among the patients
with cN3 disease. Five of them had a pCR. From the
remaining 9 patients, all patients had cT2 tumors and
seven showed a PR/CR to induction chemotherapy.
Kaplan Meier survival curves are given in Figure 4 for
all patients with pCR and cN2, pCR and cN3, not-pCR
and cN2 as well as not-pCR and cN3 following the splits
according to the upper nodes of the regression tree in
Figure 3. There was a significant effect of pCR on sur-
vival over the strata cN2 and cN3 (p = 0.0004, log rank
test) and survival differed between cN2 and cN3 patientsFigure 3 Regression tree diagram from recursive partition analysis using cl
number of patients for the split, the log rank statistic for dissimilarity betwe
subgroups are given.(p = 0.017, log rank test). Survival at 5 years was 61 ± 4%
for patients with pCR and cN2, 63 ± 17% for pCR and
cN3, and 33 ± 6% for not-pCR and cN2, as well as 11 ±
6% for not-pCR and cN3 patients, respectively.
Proportional hazard analysis of the prognostic value of
clinical and pathological characteristics on time to
progression
Proportional hazard analysis revealed that complete re-
mission by RECIST, and pCR were the sole prognostic
parameters according to the proportional hazard model
using backward selection that predicted time to progres-
sion (TTP). The hazard ratio associated with pCR on
TTP was 0.34 (0.16–0.70).
Discussion and conclusion
Important pre-treatment patient- and tumor-dependent
prognostic factors found in this study were the clinical
lymph node status, pneumonectomy, gender, adenocar-
cinoma histology, age, and Pancoast tumor localisation.
All patients received induction chemotherapy, neoadjuvant
radiochemotherapy und thoracotomy. These findings are
in accordance with the Intergroup 0139 trial which also
identified female sex as a favorable prognostic factor [2].
pCR was a strong prognostic factor for survival in this
analysis and in other studies after neoadjuvant radioche-
motherapy for locally advanced non-small cell lung cancerinical and histopathologic prognostic parameters. For each node, the
en the subgroups, and survival at 3 and 5 years (S3y, S5y) for the
Figure 4 Kaplan Meier survival curves for the subgroups of patients with pathological complete remission (pCR), and without pCR (not-pCR)
according to nodal category cN0-1, cN2, and cN3.
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with prolonged survival by improved long-term tumor
control, the association between pCR and time to progres-
sion was analysed using PHA, and pCR was again ob-
served as positive prognostic factor. The specificity for the
prediction of long term survivors decreased substantially
when the histopathologic criterium was broadened from
pCR to MNC or regression grade ≥ 2B. Devitalisation of
tumor in both the primary site and lymph nodes seems to
be important to improve prognosis of patients treated with
induction chemotherapy followed by radiochemotherapy
in lung cancer. A similar observation was made in breast
cancer after neoadjuvant chemotherapy. Disease-free sur-
vival was highest in breast cancer patients with pCR at
the primary site and the involved lymph nodes [20].
The hazard ratio for disease-free survival in comparison to
patients without histopathologic response increased from
0.45 for patients with no in situ residuals in the primary
tumor and the lymph nodes to 0.52, 0.62, and 0.73, re-
spectively, when patients with in situ residuals at the pri-
mary site, or patients with residually involved nodes but no
invasive breast cancer at the primary site, or patients with
focal invasive disease were included in the histopathologic
response definition [21]. It was therefore concluded that
ypTis, ypT1mic and ypN+ residuals alone are associated
with an increased relapse risk and should not be consid-
ered in the definition of positive histopathologic response.
Downstaging to pCR after neoadjuvant radiochemo-
therapy can improve the prognosis for cN2 and cN3 pa-
tients and yields favorable long-term survival. In the
cN2-3 group of our patients achieving pCR, five-yearsurvival was 61%, well within the range of other studies
[11]. The observation that pCR alone is a predictor of
better prognosis is reflected by the position of pCR in
the top node of the regression tree.
Selection of the optimal candidates for surgery remains
a crucial point in daily clinical practice and is strongly in-
fluenced by current restaging capabilities [11,22]. Even
considering the whole spectrum of procedures (from non-
invasive radiological tools to more invasive surgical ap-
proaches), the restaging assessment often fails to predict
the actual pathological response in this situation. Volume
response to neoadjuvant radiochemotherapy from sequen-
tial CT-studies has been found to be correlated with pCR
and prognosis after neoadjuvant radiochemotherapy by
this study and is an important preoperative prognostic
factor that, however has not the predictive power of pCR
itself. FDG-PET/CT has been investigated in this situation
adding at least some valuable information on treatment
response in these patient cohorts [23,24]. When using cut-
off levels of deltaSUVmax around 0.3 to define responders
a positive correlation with pCR was observed. Whether
PET-response to neoadjuvant radiochemotherapy is a bet-
ter prognostic factor for overall survival than CT-response
remains an open question.
The present study is a retrospective investigation of a
group of consecutive patients treated at a single institution.
Although the physicians’ team has remained constant
through the long duration of patients inclusion some
changes of the induction as well as the concurrent treat-
ment have taken place. Thus, some intrinsic bias cannot be
excluded entirely and when translating our findings into a
Pöttgen et al. BMC Cancer  (2015) 15:363 Page 9 of 10general setting of preoperative treatment this should be
taken into account.
pCR improved the survival risk discrimination between
equally sized low risk and high risk groups using a clinico-
pathologic prognostic model according to cross-validated
Kaplan-Meier curves. There is a considerable interest to
refine prognostic models for lung cancer by gene expres-
sion signatures and whole genome sequencing [25,26].
Given the dominant prognostic significance of pCR after
neoadjuvant radiochemotherapy using cisplatin containing
doublets, pCR should be included as a prognostic factor in
studies of patients after neoadjuvant radiochemotherapy.
If further treatments are considered after neoadjuvant
radiochemotherapy and resection, as in the Intergroup
0139 or the RTOG 02–29 trial [2,6], the prognostic
model including pCR might help to identify patients
who benefit most from additional postoperative treatment
or treatment intensification, respectively.
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